GD2-CAR T Cells for Pediatric Brain Tumours

The purpose of this study is to test the safety and efficacy of iC9-GD2-CAR T-cells, a third generation (4.1BB-CD28) CAR T cell treatment targeting GD2 in paediatric or young adult patients affected by relapsed/refractory malignant central nervous system (CNS) tumors. In order to improve the safety of the approach, the suicide gene inducible Caspase 9 (iC9) has been included.

Trial Details

NCT ID
NCT05298995
Phase
PHASE1
Sponsor
Bambino Gesù Hospital and Research Institute
Status
RECRUITING
Cancer Type
Brain Cancer
Interventions
  • GD2-CART01 (iC9-GD2-CAR T-cells)
Locations (sample)
  • Roma, Italy, Italy|44.99364,11.10642

Key Eligibility Criteria

  • Imaging assessments performed within 14 days of start of treatment
  • Age: 6months-30years
  • Measurable or evaluable disease on at least 2 dimensions on MRI at the time of treatment enrollment
  • Karnofsky/Lansky≥60

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →